Medinice S.A
Medinice S.A., a medical technology company, creates, develops, and commercializes minimally invasive solutions in cardiology and cardiac surgery. The company offers PacePress, a medical device to reduce the risk of complications following the implantation of cardiac electrotherapeutic devices, such as pacemakers or implantable cardioverter-defibrillators; CoolCryo, a cardiac cryoablation technol… Read more
Medinice S.A (ICE) - Net Assets
Latest net assets as of September 2025: zł77.60 Million PLN
Based on the latest financial reports, Medinice S.A (ICE) has net assets worth zł77.60 Million PLN as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł82.52 Million) and total liabilities (zł4.92 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł77.60 Million |
| % of Total Assets | 94.04% |
| Annual Growth Rate | 119.21% |
| 5-Year Change | 377.2% |
| 10-Year Change | N/A |
| Growth Volatility | 656.04 |
Medinice S.A - Net Assets Trend (2016–2024)
This chart illustrates how Medinice S.A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medinice S.A (2016–2024)
The table below shows the annual net assets of Medinice S.A from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | zł81.01 Million | +144.26% |
| 2023-12-31 | zł33.17 Million | -10.67% |
| 2022-12-31 | zł37.13 Million | -8.51% |
| 2021-12-31 | zł40.58 Million | +139.04% |
| 2020-12-31 | zł16.98 Million | +106.38% |
| 2019-12-31 | zł8.23 Million | +182.18% |
| 2018-12-31 | zł2.92 Million | -10.71% |
| 2017-12-31 | zł3.26 Million | +2048.69% |
| 2016-12-31 | zł151.95K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medinice S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1684689132.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | zł16.44 Million | 20.30% |
| Common Stock | zł766.00K | 0.95% |
| Other Comprehensive Income | zł6.90 Million | 8.52% |
| Other Components | zł56.90 Million | 70.24% |
| Total Equity | zł81.01 Million | 100.00% |
Medinice S.A Competitors by Market Cap
The table below lists competitors of Medinice S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Foseco India Limited
NSE:FOSECOIND
|
$49.49 Million |
|
Kyungdong Gas
KO:012320
|
$49.50 Million |
|
Deutsch Motors Inc
KQ:067990
|
$49.52 Million |
|
METXF
PINK:METXF
|
$49.53 Million |
|
Showbox Corp
KQ:086980
|
$49.47 Million |
|
Revival Gold Inc
OTCQX:RVLGF
|
$49.45 Million |
|
Eimco Elecon (India) Limited
NSE:EIMCOELECO
|
$49.44 Million |
|
ITM Semiconductor Co. Ltd
KQ:084850
|
$49.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medinice S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 33,166,000 to 81,010,000, a change of 47,844,000 (144.3%).
- Net income of 37,577,000 contributed positively to equity growth.
- New share issuances of 9,601,000 increased equity.
- Other comprehensive income increased equity by 667,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł37.58 Million | +46.39% |
| Share Issuances | zł9.60 Million | +11.85% |
| Other Comprehensive Income | zł667.00K | +0.82% |
| Other Changes | zł-1.00K | -0.0% |
| Total Change | zł- | 144.26% |
Book Value vs Market Value Analysis
This analysis compares Medinice S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.57x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 949.80x to 3.57x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | zł0.05 | zł43.25 | x |
| 2017-12-31 | zł0.98 | zł43.25 | x |
| 2018-12-31 | zł0.87 | zł43.25 | x |
| 2019-12-31 | zł1.89 | zł43.25 | x |
| 2020-12-31 | zł3.17 | zł43.25 | x |
| 2021-12-31 | zł7.04 | zł43.25 | x |
| 2022-12-31 | zł5.78 | zł43.25 | x |
| 2023-12-31 | zł5.19 | zł43.25 | x |
| 2024-12-31 | zł12.12 | zł43.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medinice S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 46.39%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 19987.77%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (46.39%) is above the historical average (-35.29%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -211.00% | -173.54% | 0.13x | 9.58x | zł-335.80K |
| 2017 | -15.53% | -208.69% | 0.05x | 1.50x | zł-833.67K |
| 2018 | -56.71% | -148935.44% | 0.00x | 2.59x | zł-1.94 Million |
| 2019 | -27.31% | -1366.43% | 0.01x | 1.42x | zł-3.07 Million |
| 2020 | -17.79% | -812.10% | 0.02x | 1.23x | zł-4.72 Million |
| 2021 | -7.10% | -1001.04% | 0.01x | 1.21x | zł-6.94 Million |
| 2022 | -13.27% | -2002.03% | 0.01x | 1.13x | zł-8.64 Million |
| 2023 | -15.29% | -2254.22% | 0.01x | 1.13x | zł-8.39 Million |
| 2024 | 46.39% | 19987.77% | 0.00x | 1.07x | zł29.48 Million |
Industry Comparison
This section compares Medinice S.A's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $34,608,203
- Average return on equity (ROE) among peers: -192.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medinice S.A (ICE) | zł77.60 Million | -211.00% | 0.06x | $49.49 Million |
| Adiuvo Investment SA (ADV) | $7.30 Million | -237.44% | 6.75x | $685.90K |
| Braster S.A. (BRA) | $650.00K | -601.08% | 36.39x | $2.89 Million |
| Genomtec S.A. (GMT) | $7.57 Million | -144.47% | 0.24x | $14.99 Million |
| Medicalg (MDG) | $99.19 Million | 14.04% | 0.03x | $34.29 Million |
| Synektik S.A. (SNT) | $58.33 Million | 6.18% | 0.83x | $268.09 Million |